A b s t r a c t
Identification of the 2009 H1N1 influenza A virus requires emergency use authorized (EUA)
A novel pandemic influenza A strain, 2009 H1N1 virus, was first identified in Mexico and subsequently spread, causing worldwide infection. 1 The outbreak increased demands on hospital emergency departments and laboratories. 2, 3 Rapid antigen detection immunoassays (chromatographic assays, enzyme immunoassay) are widely used in hospital and physician office settings because they require no instrumentation, are technically simple, and can provide rapid results on a continual basis. However, studies demonstrated low sensitivities when testing the 2009 H1N1 virus with rapid immunoassay (40%-70%), precluding their use in the clinical setting. [2] [3] [4] The differentiation of the 2009 H1N1 virus from seasonal H1N1 influenza A is important. Pandemic H1N1 virus is susceptible to neuraminidase inhibitors and resistant to amantadine drugs, but the opposite is true for the seasonal H1N1 virus. 1 Discontinuation of antibiotic regimens and reductions in the use of hospital isolation facilities could also result from a timely, definitive diagnosis.
The Centers for Disease Control and Prevention released an emergency use authorization (EUA) reverse transcriptasepolymerase chain reaction (RT-PCR) assay to health laboratory sites to identify the 2009 H1N1 virus. Manufacturers also developed EUA assays for this purpose. Although molecular assays are generally more sensitive and improve result turnaround times compared with traditional viral culture, they often require costly equipment, complex technical training, and additional regulatory requirements to perform. Consequently, the use of molecular diagnostics is often limited in hospital laboratories. Instead, patient diagnosis relies on traditional cell culture, antigen detection, and serologic techniques.
A 
Materials and Methods

Specimens
Study materials were obtained from remnant positive original nasopharyngeal specimens previously tested using rapid antigen detection, culture, and RT-PCR. Influenza specimens (50 influenza A/2009 H1N1; 10 influenza A/ H3, 10 influenza A/seasonal H1, and 10 influenza B) were identified and subtyped using RT-PCR methods (Pro Flu and Pro Flu+, Gen Probe, San Diego, CA). Other respiratory pathogens (10 respiratory syncytial virus [RSV] specimens, 5 specimens each for parainfluenza types 1 through 3, 5 rhinovirus, 5 adenovirus, 3 enterovirus, and 10 human metapneumovirus [hMPV] training panel specimens) were also tested with the new FA reagent. Specimens were collected using mattress or flocked type swabs, placed in universal transport medium (Copan Diagnostics; Corona, CA), stored at 2°C to 8°C for 3 to 6 days, and thereafter kept frozen at -70°C.
Shell-Vial Culture
A total of 2 R-mix shell vials (A549/Mv1Lu cells; Diagnostic Hybrids) were inoculated with aliquots (0.1 mL) of original specimens and were centrifuged, incubated for 24 hours, and harvested according to the manufacturer's prescribed protocol. Rhinovirus specimens were inoculated into MRC-5 shell vials. Monkey kidney shell vials were used to isolate enterovirus and hMPV samples (Diagnostic Hybrids).
Direct Specimens
A total of 25 microscope slides were prepared from original positive specimens (10 specimens of 2009 H1N1; 6 RSV specimens, 3 adenovirus specimens, 2 specimens each of parainfluenza 1 through 3) using a Cytospin 3 centrifuge (Thermo, Pittsburgh, PA). Additional manufacturerprepared (Diagnostic Hybrids) direct specimen training panel slides (2 each) for RSV, influenza A and B, parainfluenza 1 through 3, adenovirus, and 10 negative preparations were also included for study. The hMPV training samples (Diagnostic Hybrids; 5 each of types 1A and B2) were prepared for examination as previously described for original patient specimens.
Direct bedside specimens were prepared by collecting posterior nasopharyngeal cells using mattress or flocked swabs. Cells were then transferred on glass slides at the bedside by rolling the swab on the slide surface. Positive slides for RSV (5) and influenza A2009 H1N1 (2) and 5 negative slides were stained with the 2009 H1N1 reagent. The low quantity of bedside prepared samples precluded their value in sensitivity and specificity analysis; however, they were used to contrast different direct-specimen preparation methods with fluorescent staining quality.
FA Staining
One shell-vial monolayer was stained with virusspecific antibodies (D 3 Ultra respiratory ID kit, Diagnostic Hybrids) to confirm the presence of each virus type. hMPV and enterovirus were confirmed with hMPV (D 3 Ultra Duet IF reagent, Diagnostic Hybrids) and D 3 IFA-enterovirus (Diagnostic Hybrids) reagents, respectively. Rhinovirus was confirmed using a combination of 2 enterovirus FA reagents (D 3 IFA-enterovirus and Light Diagnostics Panenterovirus blend, Millipore, Temecula, CA), as previously described. 5 The second monolayer was stained with the new 2009 H1N1 reagent. Direct specimens were also stained and confirmed as described. Staining procedures followed specified manufacturer's directions. I evaluated the specimens. Results were subsequently confirmed (positive or negative fluorescent activity) by the virology laboratory staff members who were blinded as to the specimen identities and the expected results.
Fluorescent microscopy was done using an episcopic microscope equipped with a 100-W mercury vapor light source, a 450-to 490-nm B-2A interference excitation filter, and a 515-nm barrier filter (Filter Unit B2A, Nikon, Garden City, NY). Specimens were examined at ×100 and ×400.
Results
Shell-Vial FA Staining
The results of FA staining are given in 
Direct Specimen Testing
The 2009 H1N1 reagent produced similar results when testing laboratory-prepared direct specimens. As expected, there were fewer positive cells observed in direct slides than in culture monolayers. Low and high magnifications were needed to confirm cellular fluorescence.
Background fluorescent staining was found in some laboratory-prepared slides; however, this artifact did not readily hinder result interpretation. Conversely, background fluorescence was pronounced in bedside-prepared specimens. The method used to prepare bedside specimens (rolling cells onto a glass slide) resulted in accumulating mucus on the specimen surface and prevented adequate cellular separation, which produced cellular clumping. Both of these factors seemed to increase the background fluorescence, making the bedside-prepared materials difficult to interpret.
Low columnar epithelial cells, abundant in the posterior nasopharynx, are infected by influenza virus and readily demonstrate fluorescent activity when appropriately tested with the appropriate antibody reagents. Determination of low columnar cell types was sometimes difficult in laboratoryprepared slides. Cellular clumping and dried mucus films present on bedside-prepared slides made determination of this cell type almost impossible. An evaluation of epithelial cell numbers was not presently done to evaluate specimen adequacy (acceptance based on >20 cells per slide).
Confirmation of non-2009 H1N1 viruses produced expected positive results when testing was done using their appropriate fluorescent antibodies. Two enterovirus antibody pools were used to identify rhinovirus, as described. 5 Subtype analysis was done using neutralization techniques (adenoviruses and enteroviruses) and reverse transcriptase-polymerase chain reaction testing for seasonal and 2009 H1N1 strains of influenza A (Pro Flu, Gen Probe, San Diego, CA). Uninoculated cultures and negative slides served as control samples. † Original respiratory specimens were obtained from patients (and placed in viral transport medium) and/or were obtained from culture and direct slide training panels (D 3 Influenza A 2009 H1N1 Reagent Kit, Diagnostic Hybrids, Athens, OH). ‡ Slides were prepared using a Cytospin 3 Centrifuge (Thermo, Pittsburgh, PA) from original specimens or were obtained from manufacturer-prepared direct-specimen training materials (Diagnostic Hybrids).
❚Image 1❚ Positive fluorescent staining of 2009 H1N1 influenza A virus 24 hours after inoculation of virus in shell-vial culture (R-mix) using the D 3 Ultra H1N1 influenza A virus ID reagent (Diagnostic Hybrids, Athens, OH). Photomicrograph (scope magnification, ×200) courtesy of Diagnostic Hybrids.
Discussion
The new 2009 H1N1 FA reagent offers the first EUAcleared, nonmolecular tool to definitively identify the 2009 H1N1 virus.
The presence of influenza A virus must be established in specimens, using an alternative approved method, before using the 2009 H1N1 reagent. A proposed laboratory flowchart for using this antibody reagent is shown in ❚Figure 1❚. Specimen collection using flocked swabs over traditional mattress swabs is recommended because the former have demonstrated superior ability in collecting and releasing materials. 6 Specimen collection is critical to the success of antigen detection methods. 7 Two R-mix shell vials are inoculated as described in the study design. If the first monolayer is influenza A-negative, the second monolayer can be examined using a pool of respiratory antibodies (ie, D 3 Ultra screening reagent) to identify other common viruses.
Nasopharyngeal specimens may also be directly examined using antigen detection techniques. These assays are important in providing point-of-care testing in hospital emergency departments and physician offices on a 24-hour, 7-day basis. Despite poor sensitivity, positive results seem reliable and can be used to triage and manage hospital resource allocation. Positive influenza A specimens may then be tested using the new 2009 H1N1 antibody reagent to assess the need for patient isolation and appropriate care management with respect to particular 2009 H1N1 infection risks (eg, pregnancy and obesity).
Poor sensitivities demonstrated by enzyme immunoassay and chromatographic immunoassays for the 2009 H1N1 virus 2-4 might necessitate retesting of negative specimens using FA techniques or shell-vial culture, if available. FA demonstrated greater sensitivity for 2009 H1N1 virus than other rapid immunoassay methods. 2, 3 Compared with PCR, FA negative predictive values of 96% or more were recently reported, also making it an effective test to rule out influenza A. 7 Direct specimens negative for influenza A may be additionally tested using a pool of respiratory antibodies that specifically identify a number of different respiratory viruses (D 3 Ultra Duet respiratory ID kit, Diagnostic Hybrids). Result times of approximately 1 or 2 days are obtainable using culture. Direct testing can provide results within hours.
Shell-vial culture methods produced easily recognizable positive results at low (×100) magnification. In facilities not equipped to perform culture, laboratory-prepared microscope slides using a Cytospin centrifuge provide rapid specimens with excellent morphologic detail. Cytospin slides are recommended over bedside-prepared materials because the former were easier to interpret and produced much less background fluorescence.
In hospitals lacking molecular diagnostics, outsourcing specimens for 2009 H1N1 testing can be costly (approximately $200 per test) and results are often delayed because of the needed time for triaging, handling, and transporting patient specimens. Our laboratory calculated the mean time from specimen collection to the availability of RT-PCR results to be 5.69 ± 0.37 days, offering little value to patient care. 3 
Conclusion
The new 2009 H1N1 FA reagent demonstrated excellent sensitivity and specificity when tested by culture and direct immunofluorescent methods using a variety of respiratory viruses. It is important to note that the 2009 H1N1 reagent provides traditional, nonmolecular laboratories an inexpensive, rapid, and accurate in-house method to diagnose 2009 H1N1 virus, without expensive equipment and intensive staff training. 
